◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

FGFR3-targeted therapeutics (vosoritide / infigratinib / sotuletinib)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

Disease-specific therapy for achondroplasia/skeletal dysplasia driven by FGFR3 G380R gain-of-function mutation. Dylan has normal stature (6'0-6'1) and no FGFR3 pathology. Would change only if a pediatric/adolescent FGFR3-mutation patient needed it (not Dylan).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    Growth plates fused; no FGFR3 pathology.

  • 30-50, executive maintenance
    NOT-RELEVANT
  • 50+, mild cognitive decline
    NOT-RELEVANT
  • Anxiety-prone
    NOT-RELEVANT
  • High athletic load, tested status
    NOT-RELEVANT
  • Sleep-disordered
    NOT-RELEVANT
  • Recovery-focused
    NOT-RELEVANT
  • Strength/anabolic-focused
    NOT-RELEVANT

    drugs do not affect muscle or hormonal axes meaningfully.

  • Special case — pediatric achondroplasia caregiver
    V

    is now standard of care for children ≥5 with open growth plates. Discuss with pediatric endocrinologist.

▸ Subjective experience (deep)

Pediatric patients on vosoritide report mild injection-site reactions, occasional transient hypotension (due to NPR-B vasodilatory effect), and unchanged general well-being. No "feel-different" effect — purely growth-plate targeted.

▸ Tolerance + cycling deep dive
  • Vosoritide: chronic daily dosing throughout active growth years
  • TKIs: continuous dosing in trials
  • No cycling protocols relevant outside disease management
▸ Stacking deep dive

Synergistic with

  • N/A in biohacker context. Within achondroplasia care — adequate vitamin D, calcium, nutrition support growth.

Avoid stacking with

  • Other anti-hypertensives (vosoritide hypotension stacking)
  • Strong CYP3A modulators with TKIs

Neutral / safe co-administration

N/A for biohacker use.

▸ Drug interactions deep dive
  • Vosoritide: peptide, no CYP. Pharmacodynamic interaction with antihypertensives.
  • Infigratinib/sotuletinib: extensive CYP3A4 metabolism, P-gp substrate. Avoid grapefruit, strong inducers/inhibitors.
▸ Pharmacogenomics
  • FGFR3 G380R is the achondroplasia-defining mutation (~98% of cases). Heterozygous lethal in homozygotes (rare).
  • Other FGFR3 activating mutations: hypochondroplasia, thanatophoric dysplasia, SADDAN syndrome.
  • Adult populations with normal FGFR3 derive zero benefit.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Voxzogo (vosoritide) Rx BioMarin via specialty pharmacy ~$320,000/yr high Pediatric achondroplasia only; gated distribution
Truseltiq (infigratinib) QED Therapeutics / Helsinn varies high Oncology only; repurposing trial-restricted
Lytgobi (futibatinib) Taiho Oncology ~$24,000/mo high Oncology only
Research-chem None reputable N/A N/A Do not pursue

For Dylan: No accessible or appropriate path.

▸ Biomarkers to track (deep)
  • In achondroplasia care: annualized growth velocity, height-Z-score, body proportions, vitamin D, ALP, sleep apnea screening (achondroplasia-related, not drug-related)
  • For Dylan: N/A
▸ Controversies / open debates Live debate
  • Adult FGFR3 inhibition for height? Once growth plates fuse (typically 16-18 in males), no skeletal lengthening will occur. Some ill-advised forums discuss "reopening growth plates" with FGFR3 blockade — biologically implausible without first re-creating cartilaginous epiphysis (which would require regenerative-medicine-level intervention not yet available).
  • Quality-of-life vs medicalization debate: Within achondroplasia community, some advocacy groups oppose normalizing growth as pathologizing identity. Outside scope for compound file but informs prescribing context.
  • TKI repurposing safety: Adapting oncology FGFR inhibitors at pediatric low doses requires caution — long-term pediatric safety not yet established.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT HIGH. Filed as queue clarification: entry was "fgfr3 — clarify which compound." The most coherent interpretation is the vosoritide / FGFR3-TKI achondroplasia therapy class, all of which are disease-specific and irrelevant for Dylan. Sotuletinib (TAS-120/futibatinib) is an oncology drug and should not be confused with achondroplasia therapy.
▸ Open questions / gaps Open
  • Whether any FGFR3 modulator gets repurposed for adult bone/cartilage regeneration (chondrocyte renewal in osteoarthritis): possible future angle but no current data.
  • Recifercept Phase 2 readouts in adolescents with achondroplasia.
▸ Sources (full, with our context)
Back to compact view